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http://dx.doi.org/10.1016/j.jacl.2015.08BACKGROUND: Circulating noncholesterol sterols/stanols (NCS) are used in clinical lipidology as
surrogate measures of cholesterol synthesis and absorption, where they can be valuable tools in assess-
ing cholesterol metabolism and personalizing therapies in patients with dyslipidemia.
OBJECTIVES: To describe the distributions of plasma NCS concentrations and inter-NCS correla-
tions in a large cohort of American patients constituting a clinical laboratory database, and to investi-
gate the relationship between circulating NCS, age, sex, and apolipoprotein E (APOE) genotype.
METHODS: A total of 667,718 patient blood samples submitted for testing to Health Diagnostic
Laboratory, Inc. (Richmond, VA) were analyzed for cholesterol absorption markers (sitosterol, campes-
terol, and cholestanol) and one cholesterol synthesis marker (desmosterol). NCS percentiles were
determined, along with intermarker correlations (Pearson’s R). Analysis of variance was used to assess
the effect of age and sex on NCS level, and to evaluate the relationship between cholesterol synthesis/
absorption status and APOE genotype in a subset of 336,866 patients.
RESULTS: Mean NCS concentrations were: sitosterol, 2.45 mg/mL; campesterol, 3.3 mg/mL; choles-
tanol, 2.92 mg/mL; and desmosterol 0.99 mg/mL. The correlations between each NCS and its ratio to
total cholesterol ranged from 0.72 (cholestanol) to 0.94 (desmosterol). NCS levels were significantly
affected by age and sex (P , .0001), and prevalence of cholesterol hyperabsorption was higher in
APOE ε4 allele carriers compared with the other APOE genotypes.
CONCLUSIONS: We have described sample distributions of NCS biomarkers and characterized their
relationship to age, sex, and APOE genotype. These data may facilitate research into altered cholesterol
homeostasis and human disease, and help physicians optimize lipid-lowering therapies.
 2015 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).for Health Improvement and Tech-
boratory, 737 N. 5th Street, Rich-
for publication August 21, 2015.
ociation. Published by Elsevier Inc. T
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.003Introduction
Sterols consist of a family of aromatic triterpine
molecules found in plants (phytosterols) and animals
(zoosterols). They perform a variety of functions, modu-
lating cell membrane fluidity and influencing cell signaling
through their structural role in lipid rafts. Although foundhis is an open access article under the CC BY-NC-ND license (http://
808 Journal of Clinical Lipidology, Vol 9, No 6, December 2015in some plants, cholesterol is predominantly a zoosterol and
serves as a precursor for steroid hormones and bile acids in
humans. However, as excess cellular cholesterol may
crystallize and lead to cell death, cholesterol homeostasis
within the body is a tightly regulated balance between
endogenous synthesis, exogenous (dietary) absorption, and
excretion (bile acids or biliary cholesterol).1,2
The term noncholesterol sterols, or xenosterols, encom-
passes all sterols that are structurally similar to cholesterol,
including phytosterols (eg, campesterol and sitosterol, which
differ by methyl and ethyl groups at position C-24; Fig. 1),
and several cyclical precursor molecules. More than 20
enzymes are used throughout the two cholesterol synthesis
pathways, leading to either lathosterol or desmosterol, but
because of a cholesterol ‘‘metabolon’’ there is much interac-
tion between the two pathways.3 Phytosterols cannot be syn-
thesized by humans and are always derived from the diet.4
Overall intestinal absorption of free cholesterol is regulated
by an interplay between the enterocyte- and hepatobiliary-
located sterol influx membrane transporter, Niemann-Pick
C1-Like 1 (NPC1L1), and a heterodimer consisting of two
ATP-binding cassette (ABC) efflux transporters, subfamilyFigure 1 Chemical structures and formulae of the major cholesterol h
campesterol differ by having ethyl or methyl groups, respectively, at ca
double bond at D5 but one at D7, and desmosterol has a diene at D5 amembers 5 and 8 (ABCG5 and ABCG8, respectively).2
The latter are found on the apical surface of enterocytes
and the hepatobiliary interface, and are responsible not only
for efflux of excess cholesterol into the gut lumen and bile
to avoid cellular injury1 but also for preventing the bodily
accumulation of dietary phytosterols. High circulating levels
of cholesterol, and potentially phytosterols, are thought to
play a causal role in atherogenesis, which occurs when
sterol-laden apolipoprotein B (apoB)–containing lipoproteins
invade the arterial wall, are oxidized, and initiate a maladap-
tive inflammatory response.5 Indeed, common genetic vari-
ants associated with serum phytosterol levels affect risk for
coronary artery disease.6,7 Stanols are sterols with a saturated
double bond at the 5a position (Fig. 1) and are derived either
from the diet or as a gut microbial byproduct of cholesterol
metabolism; this family includes cholestanol and coprosta-
nol.8–10 Both phytosterols and stanols compete with choles-
terol for absorption, and hence are used as functional foods
or supplements in the treatment of hypercholesterolemia.11
Measuring plasma cholesterol directly does not reveal
whether its origin is cellular synthesis or intestinal absorption.
The sterol-binding domains ofNPC1L1 andABCG5/G8 haveomeostasis biomarkers. With respect to cholesterol, sitosterol and
rbon 24; cholestanol has no double bond at D5, lathosterol has no
nd D24.
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and stanols. Because they cannot be synthesized in the body
and have significantly reduced absorption capability
compared with cholesterol, the plasma measurement of
noncholesterol sterols/stanols (NCS) can establish whether
elevated cholesterol levels are due in part to hyperabsorption,
hypersynthesis, or a combination of both or neither.4,12–16
Serum concentrations of certain NCS have been validated in
clinical trials as tools for the diagnosis of genetic NCS disor-
ders, the evaluation of cholesterol homeostasis and cardiovas-
cular risk, and clinical trial assessment of lipid-lowering
therapies.13,17–22Measurement ofNCS is required to diagnose
most of the rare lipidoses such as phytosterolemia, cerebroten-
dinous xanthomatosis, Smith-Lemli-Opitz syndrome, des-
mosterolosis, and lathosterolosis.23
These cholesterol homeostasis biomarkers have been
brought to the bedside over recent years, as liquid chroma-
tography and/or mass spectrometry lipidomic assays have
replaced the more complex, invasive methods of evaluating
cholesterol synthesis and absorption.22,24–27 Knowledge of an
individual’s cholesterol absorption and synthesis status can
help clinicians better understand how these processes are
related to atherosclerosis andhowNCSsupplements and other
drugs modulate cholesterol homeostasis.28,29 Such informa-
tion is increasingly used to help guide lipid-lowering strate-
gies and therapeutic lifestyle choices in individual
patients.30 Sitosterol and campesterol are the most commonly
tested NCS, along with cholesterol synthesis precursors des-
mosterol and lathosterol (Fig. 1).13,14,31 Levels of sitosterol,
campesterol, and cholestanol have been evaluated in many
studies relating increased cholesterol absorption to cardiovas-
cular risk.19,20,22 NCS markers reflective of cholesterol
synthesis or absorption are reported either as absolute concen-
trations or as ratios to total cholesterol (TC), the latter to
normalize differences caused by variable levels of lipopro-
teins, inwhichNCSare trafficked.18,21Although the twomea-
sures are correlated, and there is scientific evidence to support
the predictive value of each, there is also debate as to which
should be used in clinical practice.13,16,18,21,30,32,33
Various factors are known to influence cholesterol
homeostasis, including nutritional, physiological, pharma-
cological, and genetic factors; for example, specific poly-
morphisms of the NPC1L1,7 ABCG5/ABCG8,6 or
apolipoprotein E (apoE) genes (APOE).18,34 APOE has
three allele ‘‘genotypes’’—ε3, ε4, and ε2—encoding 3 pro-
tein isoforms (respectively, E2, E3, and E4). The three
apoE protein isoforms are defined by the presence or
absence of cysteine (Cys) or arginine (Arg) at amino acid
positions 112 and 158, in turn determined by the haplotype
of two underlying single nucleotide polymorphisms (SNPs)
in exon 4 of the APOE gene. SNP rs429358 determines the
amino acid at 112 and SNP rs7412 at 158. The E2 isoform
consists of Cys112/Cys158, the E3 isoform comprises
Cys112/Arg158, and E4 is Arg112/Arg158. The three
apoE isoforms differentially affect plasma lipid and
lipoprotein concentrations as they have different affinities
for various membrane receptors and lipases.35Given the increasing interest in using NCS as bio-
markers of cholesterol homeostasis in the clinical setting, it
is important to establish age- and sex-based norms against
which physicians can evaluate their patients. The aims of
this study were three fold: first, to describe the concentra-
tion distributions of four cholesterol homeostasis bio-
markers in a large and unselected cohort of clinical
laboratory serum samples collected over the course of
2.5 years; second, to investigate the relationship between
these cholesterol homeostasis biomarkers and traditional
lipid levels; and third, to establish the relationship between
NCS concentrations and APOE genotype, along with other
demographic variables such as age and sex.Material and methods
Subjects
This retrospective cross-sectional analysis included data
from blood samples submitted for testing to Health
Diagnostic Laboratory, Inc (HDL, Inc., Richmond, VA) as
part of routine clinical cardiovascular risk assessment
between January 2012 and May 2014. Absolute concentra-
tions of cholesterol absorption biomarkers (sitosterol,
campesterol, and cholestanol) and the cholesterol synthesis
biomarker (desmosterol), their ratios to TC, traditional lipid
assessments, and APOE genotype (in a subset of patients)
were extracted without any linked patient identifiers except
age and sex. No family history, medical history, current
medications, or vital signs were available. A waiver of
informed consent and Health Insurance Portability and
Accountability Act authorization requirements for this
study (using only deidentified and aggregated laboratory
data) was obtained from the Copernicus Group IRB
(Research Triangle, NC).
Laboratory methods
Blood samples were drawn after an overnight fast and
shipped with cold packs to HDL, Inc for biomarker testing.
Samples were prepared at each clinical site according to
standardized instructions appropriate for specimen type
(BD Vacutainer PPT ‘‘Pearl Top’’ with EDTA and gel were
used for sterol tests, BD Vacutainer SST ‘‘Tiger Top’’ tubes
for traditional lipid tests, and BD Vacutainer K2 Whole
Blood ‘‘Lavender Top’’ tubes for APOE genotyping),
received by HDL, Inc within 24 hours, and tested immedi-
ately. For the NCS assays, plasma samples were saponified
and extracted, then rapid chromatographic separation was
achieved with a water:methanol:acetonitrile gradient using
a reversed phase high-performance liquid chromatography
column. Detection was performed in positive ion mode
on an AB Sciex Triple Quad 5500 Liquid Chromatography
Tandem Mass Spectrometry (LC-MS/MS) System. APOE
genotyping was performed by TaqMan assay (Applied Bio-
systems Inc, Carlsbad, CA). Low-density lipoprotein
810 Journal of Clinical Lipidology, Vol 9, No 6, December 2015cholesterol (LDL-C) and high-density lipoprotein choles-
terol (HDL-C) were measured using direct enzymatic as-
says (Beckman-Coulter Biomedical Ltd, Co Clare,
Ireland). Triglyceride assay was performed using standard
automated enzymatic methods (Roche Diagnostics, Indian-
apolis, IN).
Statistical methods
Population distributions and percentile cutpoints were
determined for each NCS, along with intermarker correla-
tions (Pearson’s R). The effects of age and sex on NCS
level were assessed by multifactorial analysis of variance
(ANOVA). Biomarkers were inspected for normality and
were transformed using the natural logarithm as necessary
to improve the normality assumption for ANOVA. In the
subset of patients with APOE genotype results, values for
each marker were compared across genotype by ANOVA,
with post hoc testing compared with the APOE ε3/ε3 group
controlled using Dunnett-adjusted P values , .05 for statis-
tical significance. NCS levels for each patient sample were
categorized according to the 25th and 75th percentiles of
the large cohort as reflecting hypoabsorption/hyperabsorp-
tion or synthesis. Pearson’s chi-square test was used to
compare incidence of each category according to APOE ge-
notype. All analyses were performed using SAS software
(version 9.4; SAS Institute).Results
NCS population distributions and percentile
cutpoints
Fasting lipid and NCS data were available for 667,718
patients (meanage 566 15years, 47%male).Thedistribution
of plasma concentrations for sitosterol, campesterol,Figure 2 Distributions of assessed noncholesterol sterols/stanols throu
tanol, (D) desmosterol. Vertical dotted lines indicate the 25th, 50th, ancholestanol, and desmosterol are shown in Figure 2, with
the dashed lines representing the 25th, 50th, and 75th percen-
tile of eachmarker.Distributionswere notnormal (kurtosis for
all markers was .17) and are presented in Figure 2 only
through the 99th percentile, as each marker had a long tail ex-
tending at least 30 standard deviations above the mean. The
mean values and percentile cutpoints for each marker, and
their respective ratios with TC, are presented in Table 1. The
absolute mean concentrations in mg/mL were as follows:
sitosterol, 2.45 (interquartile range [IQR]: 1.56–3.01); cam-
pesterol, 3.3 (IQR: 2.10–4.12); cholestanol, 2.92 (IQR:
2.23–3.42); and desmosterol, 0.99 (IQR: 0.58–1.18). The
99th percentile cutpoint values for the absorption
markers (mg/mL) were as follows: sitosterol $6.94,
campesterol $9.49, and cholestanol $6.05. We identified
18 patients with sitosterol values .30 mg/mL; these individ-
uals most likely have significant loss of function of ABCG5
or ABCG8, with an incidence in this sample of 0.0027% (ie,
3 per 100,000). Furthermore, the 99th percentile cutpoint for
desmosterol (used to support a diagnosis of desmosterolosis)
was$2.83 mg/mL in this cohort.
Relationships between different cholesterol
homeostasis markers
As shown in Table 2, sitosterol and campesterol were
highly correlated (R 5 0.90, P , .0001), sitosterol and cho-
lestanol slightly less so (R 5 0.63, P , .0001), and sitos-
terol and desmosterol hardly at all (R 5 0.01, P , .05).
Interestingly, cholestanol was more strongly correlated
with TC (R 5 0.56), LDL-C (R 5 0.45), and HDL-C
(R 5 0.39) than were either of the sterol absorption
markers or desmosterol. Reflecting the imperfect correla-
tion between concentrations of the cholesterol absorption
markers, only 13% of the cohort was above the 75th
percentile of all three, whereas 38% of the cohort was
above the 75th percentile of any one. The pairwisegh the 99th percentile. (A) Sitosterol, (B) campesterol, (C) choles-
d 75th percentile cutpoints (N 5 667,718).
Table 1 Percentile cutpoints for noncholesterol sterols/stanols and their ratios to total cholesterol (N 5 667,718)
Biomarker Mean (SD) Minimum 1st 25th 50th 75th 99th Maximum
Sitosterol 2.45 (1.39) 0.10 0.66 1.56 2.18 3.01 6.94 165.60
Sitosterol/TC 129.16 (73.96) 0.00 37.00 83.00 114.60 158.00 367.00 13,119.00
Campesterol 3.33 (1.83) 0.18 0.81 2.10 2.96 4.12 9.49 112.80
Campesterol/TC 181.23 (98.68) 0.00 49.00 115.00 160.50 222.90 520.00 6256.30
Cholestanol 2.92 (1.00) 0.28 1.26 2.23 2.76 3.42 6.05 40.37
Cholestanol/TC 161.90 (46.06) 0.00 83.00 130.30 155.00 186.00 304.00 3355.00
Desmosterol 0.99 (1.24) 0.06 0.14 0.58 0.85 1.18 2.83 127.40
Desmosterol/TC 54.37 (71.91) 0.00 9.50 36.00 48.00 62.00 139.00 8056.00
TC 181.41 (43.38) 37.00 99.00 151.00 178.00 207.00 301.00 1386.00
LDL-C 108.00 (36.32) 9.00 41.00 82.00 105.00 130.00 207.00 628.00
HDL-C 56.39 (16.94) 3.00 29.00 44.00 53.00 65.00 110.00 216.00
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; TC, total cholesterol.
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and its ratio to TC were as follows: 0.89 (P , .0001) for
sitosterol vs sitosterol/TC ratio, 0.89 (P , .0001) for cam-
pesterol vs campesterol/TC ratio, 0.72 (P , .0001) for cho-
lestanol vs cholestanol/TC ratio, and 0.94 (P , .0001) for
desmosterol vs desmosterol/TC ratio (Table 2).
Effect of age and sex on circulating NCS levels
Levels of all four NCS markers were significantly
affected by both age and sex, as shown in Figure 3
(P , .0001). Multifactorial ANOVA found significant
age ! sex interactions for sitosterol (F 5 161,
P , .0001), campesterol (F 5 218, P , .0001), cholestanol
(F 5 1623, P , .0001), and desmosterol (F 5 807,
P , .0001). In women, levels of all three absorption
markers increased significantly with advancing age—most
notably during the fifth decade—while desmosterol levels
tended to increase slightly from the third to fifth decade
and decline thereafter. These trends may be at least partly
due to the shift toward cholesterol absorption vs synthesis
that begins in women in the third and/or fourth decade
and peaks at or just after the fifth decade, when most
women experience menopause. In contrast, despite age-
related increases in cholesterol absorption markers duringTable 2 Relationships between levels of cholesterol absorption/syn
Biomarker Sitosterol Campesterol Cholestano
Sitosterol 1.00
Campesterol 0.90 1.00
Cholestanol 0.63 0.65 1.00
Desmosterol 0.004* 0.003* 0.05
TC 0.24 0.27 0.56
LDL-C 0.17 0.20 0.45
HDL-C 0.27 0.23 0.39
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
Pearson’s correlations (R) determined by pairwise correlation. All correlatiothe third decade (most pronounced for sitosterol, which
continued to increase through the fourth decade), levels
of all four markers declined significantly with advancing
age in men.
For a subset of the cohort described previously
(n 5 336,866), APOE genotype data were available.
Table 3 summarizes the mean concentrations of NCS
markers according to APOE genotype and the observed fre-
quency of each genotype. The mean age of this subgroup
was 54 6 16 years, of whom 56% were women. The
APOE genotype distribution was 1% 2/2, 11% 2/3, 2%
2/4, 61% 3/3, 23% 3/4, and 2% 4/4. In general, carriers of
the APOE ε2 allele (ie, APOE genotypes 2/2, 2/3, and
2/4) tended to have lower levels of absorption markers
compared with the APOE ε3 homozygotes, whereas carriers
of the APOE ε4 allele (ie, APOE genotypes 3/4 and 4/4)
tended to have higher levels. The proportions of cholesterol
hyper- (above the 75th percentile) and hypo-absorbers
(below the 25th percentile) or -synthesizers are shown for
each APOE genotype in Figure 4. The percentage of patients
who were hyperabsorbers (defined by increased sitosterol,
campesterol, and cholestanol) was higher for the APOE
3/4 and 4/4 genotype groups (and the percentage of those
with hypoabsorption was correspondingly lower) than that
for the APOE 3/3 genotype, whereas the reverse was truethesis markers and traditional cholesterol measures
l Desmosterol TC LDL-C HDL-C
1.00
0.21 1.00
0.19 0.86 1.00
0.02 0.37 0.09 1.00
cholesterol; TC, total cholesterol.
ns were statistically significant, P , .0001, except for *P , .05.
Figure 3 Effect of age and sex (in 10-year increments from age 30 to 80 years) on noncholesterol sterol/stanol concentrations,
N 5 667,718. (A) Sitosterol, (B) campesterol, (C) cholestanol, (D) desmosterol.
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the APOE genotype groups were similar, but much less pro-
nounced, for desmosterol.Discussion
Clinical testing of NCS markers of cholesterol homeo-
stasis has been increasing in recent years, allowing this
descriptive presentation of distributions and percentiles
from a very large clinical laboratory cohort in the setting
of routine clinical care (Table 1). As this random sample of
our clinical laboratory cohort consists entirely of patients of
providers who deal with cardiometabolic issues and orderTable 3 Patient characteristics and noncholesterol sterol/stanol lev
APOE genotype 2/2 2/3 2/4
N (% of total) 2013 (0.6) 37,258 (11.1) 7555 (2.2
Sex (% F) 56 56 56
Age, y 54.1 (16.0) 53.8 (15.8)* 53.3 (15
Sitosterol 2.28 (1.21)* 2.28 (1.22)* 2.39 (1.2
Campesterol 3.25 (1.77) 3.12 (1.66)* 3.29 (1.7
Cholestanol 2.83 (1.09)* 2.79 (0.97)* 2.92 (0.9
Desmosterol 1.05 (1.65) 1.01 (1.22)* 1.01 (0.9
F, female.
*Significant differences compared with APOE 3/3 genotype adjusted for agbeyond typical laboratory testing, caution should be used
when generalizing these results to the ‘‘apparently healthy’’
US population. However, in this study, the mean circulating
NCS values were broadly consistent with those of other
studies,17,18,25,36,37 whereas the sheer sample size—to our
knowledge, the largest to date reporting NCS distribu-
tions—allowed us to generate percentile cutpoints, which
may serve as a potential population reference to facilitate
research into altered cholesterol homeostasis and human
disease. Although routine use of such testing is not advo-
cated in the general population, these data may help physi-
cians select the most optimal lipid-lowering therapies for
their patients by enabling prompt recognition of individuals
with hyper- or hypo-absorption or -synthesis. It may alsoels by APOE genotype
3/3 3/4 4/4
) 205,452 (61.0) 76,815 (22.8) 7773 (2.3)
56 56 57
.5) 53.3 (15.8) 52.9 (15.5)* 52.0 (15.9)*
6)* 2.43 (1.45) 2.52 (1.34)* 2.67 (1.47)*
8) 3.30 (1.80) 3.43 (1.84)* 3.61 (1.99)*
7) 2.94 (0.99) 3.06 (1.05)* 3.20 (1.10)*
8)* 1.06 (1.14) 1.07 (1.14)* 1.06 (0.99)
e and sex, P , .0001 (N 5 336,866).
Figure 4 Prevalence of hypoabsorption (below 25th percentile) or hyperabsorption (above 75th percentile) or synthesis according to
APOE genotype, as indicated by noncholesterol sterol/stanol levels (A) sitosterol, (B) campesterol, (C) cholestanol, (D) desmosterol. As-
terisks and daggers indicate significant differences compared to APOE 3/3 genotype, P , .001.
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sterol absorption that could inform decisions about multi-
therapy options directed at reducing absorption (eg, ezeti-
mibe, phytosterol esters, stanol esters, probiotics, or other
functional food supplements).38–40
We measured both absolute NCS concentrations and
their ratios to TC in this study, to explore differences and
relationships between the alternate metrics. The absolute
measures were strongly but variably correlated to their
corresponding ratios to TC, although the imperfect corre-
lations among absolute levels of the cholesterol absorption
markers highlights the increased sensitivity afforded by
assessing more than one.41 In this era of widespread statin
use, although the ratio is the most commonly used NCS
measure, it may not be the best indicator of cholesterol ab-
sorption and/or synthesis because TC can change—due to
variations in LDL-C—even when there is no change in
the absolute concentration of the NCS. Indeed, van Himber-
gen et al (2009) advise using the ratios to demonstrate the
biomarkers are independent of cholesterol when analyzing
absorption and/or synthesis differences between 2 groups,
but using absolute levels of the biomarkers when investi-
gating relationships between the absorption and/or synthe-
sis markers and cholesterol, to avoid masking the variable
TC and LDL-C that is of primary interest.32 Others have
suggested using an absorption-to-synthesis marker ratio,
such as phytosterol:lathosterol or phytosterol:desmosterol,
as a tracer of cholesterol absorption.42 More recently, giventhat NCS marker levels can be affected by common factors
such as diet, metabolic disease (diabetes), and drugs (sta-
tins), it has been recommended that measuring multiple
NCS biomarkers, with inclusion of at least one absolute
concentration and serial testing to establish individual set-
points, is the best approach for the evaluation of cholesterol
homeostasis.16,30
Patients with absolute NCS markers above 99th percen-
tile readings almost certainly have a genetic issue at play
(eg, variable loss of function of ABCG5 or ABCG8), and
our database identified more than 6000 individuals in this
clinical laboratory cohort with such markedly elevated
concentrations. The long-term implications are not known,
unless the absorption markers enter into the currently
accepted phytosterolemic range (eg, sitosterol .100–
300 mg/mL).43,44 Of particular interest are those individuals
with 99th percentile concentrations of desmosterol. No
known clinical entity has been described in such patients,
but abnormal accumulation of desmosterol underlies
many of the homeostatic, including inflammatory re-
sponses, of foam cells and hepatic Kupffer cells and is
also related to hepatitis C replication, fatty liver disease,
and diabetes.45,46 It is also worth noting that the cholesterol
synthesis inhibitor triparanol, formerly used to reduce total
and LDL-C, but which blocks the conversion of desmos-
terol to cholesterol, has been shown to cause significant
desmosterolemia, associated with cataracts, alopecia, and
accelerated atherosclerosis.47 In general, patients with
814 Journal of Clinical Lipidology, Vol 9, No 6, December 2015insulin resistance, metabolic syndrome, or excess visceral
fat tend to have significantly elevated markers of choles-
terol synthesis driven by hyperinsulinemia.21,48 On the
other hand, reduced serum desmosterol correlates with ce-
rebrospinal fluid desmosterol and has been validated as a
potential biomarker of Alzheimer’s disease.45,49
Our findings further suggest that age, sex, and APOE ge-
notype are important considerations for the clinical inter-
pretation of NCS values. Women showed increased
cholesterol absorption with advancing age (especially after
menopause) whereas in men, a slight increase in cholesterol
absorption toward middle age was followed be a decline
thereafter in both absorption and synthesis. The decline in
cholesterol synthesis with advancing age has been reported
in at least one prior study, although circulating cholesterol
levels tend to increase with age.50 However, prospective
analysis of the Framingham Offspring Study cohort over
a 10-year period found this to be true for some markers
of cholesterol synthesis, but not all.51 Previous investiga-
tions into sex-specific differences in NCS levels have
generated conflicting findings.18 In the Framingham
Offspring cohort study, after controlling for standard
CVD risk factors, cholesterol synthesis markers were asso-
ciated with reduced incidence of myocardial infarction and
coronary death in women, but higher risk in men.51 It is
interesting in this regard that elevated desmosterol levels
have been shown to predict worsening hyperglycemia and
5-year conversion to type 2 diabetes in a male population
cohort.46 Our results suggest that the postmenopausal shift
toward cholesterol hyperabsorption may constitute an
important and modifiable cardiovascular risk factor for
women in their later years.
Data regarding the effect of APOE genotype on the effi-
ciency of cholesterol absorption is mixed, but has never
been investigated in a database of this enormity.18,52–56 In
this clinical cohort, a subset (n 5 136,701) of which we
have previously shown has an APOE genotype distribution
reasonably representative of the US population,57 we
observed the prevalence of hyperabsorption biomarkers to
be higher, and that for hypoabsorption to be lower, in those
with the APOE 3/4 and 4/4 genotypes. Perhaps the
decreased LDL receptor–mediated clearance of apoB parti-
cles conferred by the APOE ε4 allele triggers a reflex hy-
perabsorption. If true, ezetimibe might be a useful
therapy in achieving apoB (LDL-C) goals of therapy.
Numerous studies have evaluated the effect of APOE al-
leles on statin responsiveness, with mixed results. Some
have shown decreased statin-induced reductions of LDL-C
in those with APOE ε4 alleles.58 One could hypothesize
that any statin hyporesponsiveness that may exist in ε4 car-
riers could be related to the increased incidence of choles-
terol hyperabsorption as reported here. Variation in study
findings may be at least partly attributable to differences
in ethnic composition and medication use of the different
populations under study. Nevertheless, monitoring NCS
levels for evidence of cholesterol hyperabsorption mighttherefore be prudent in APOE ε4 allele carriers, who are
already at heightened risk of coronary artery disease.59
The major strengths of our study include the measure-
ment and comparison—using state-of-the-art sterol assay
methodology—of both absolute NCS levels and their ratio
to cholesterol, along with the sheer size of the cohort
analyzed, which has allowed us to establish NCS level per-
centiles and explore the effect of APOE genotype, sex, and
gender in a cohort broadly representative of the US popula-
tion. We acknowledge limitations to this study: there was
no direct (invasive) clinical determination of cholesterol ab-
sorption or synthesis, only one synthesis sterol biomarker
(desmosterol) was analyzed, there was a lack of informa-
tion on drug use, and patients were not stratified according
to clinical diagnosis (eg, diabetes and/or metabolic disease)
or menopausal status (women).
In conclusion, the information presented here, from a
very large clinical laboratory data set of cholesterol
synthesis and absorption biomarkers, may be useful in
helping to establish US population percentiles, recognizing
the incidence of several genetic lipidoses. Such cutpoints
might also aid in selecting therapeutic lifestyles that
recommend or do not recommend absorption-related func-
tional foods and in the optimization of statin therapy or
cholesterol absorption blocker to achieve desired lipid and/
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